

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM797336

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT		
EFFECTIVE DATE:	07/26/2022		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cidara Therapeutics, Inc.		12/13/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Melinta Therapeutics, LLC		
Street Address:	389 Interpace Parkway, Suite 450		
City:	Parsippany		
State/Country:	NEW JERSEY		
Postal Code:	07054		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	88718579	REZZAYO	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-813-5900		
Email:	anicolescu@fzlz.com		
Correspondent Name:	Allison Strickland Ricketts		
Address Line 1:	Fross Zelnick Lehrman & Zissu, P.C.		
Address Line 2:	151 West 42nd Street, 17th Floor		
Address Line 4:	New York, NEW YORK 10036		
ATTORNEY DOCKET NUMBER:	MELI 2223731		
NAME OF SUBMITTER:	Anca Nicolescu		
SIGNATURE:	/ancanicolescu/		
DATE SIGNED:	03/24/2023		
Total Attachments: 1			
source=Executed Confirmatory Assignment - REZZAYO (F4932867x96B9E)#page1.tif			

CH \$40.00 88718579

CONFIRMATORY ASSIGNMENT


WHEREAS, Cidara Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, with an address of 6310 Nancy Ridge Drive, Suite 101, San Diego, California, 92121 (“Assignor”), owned the trademark listed below (hereinafter, the “Trademark”):

TRADEMARK	U.S. SERIAL NO.
REZZAYO	88718579

WHEREAS, Melinta Therapeutics, LLC, a limited liability company organized and existing under the laws of Delaware, with an address of 389 Interpace Parkway, Suite 450, Parsippany, New Jersey, 07054 (“Assignee”), acquired the Trademark as part of the acquisition of the ongoing and related business of the Assignor to which the mark pertains and all associated goodwill in the Trademark, effective as of July 26, 2022;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor hereby confirms the assignment to Assignee, effective July 26, 2022, of all right, title, and interest in and to the above-named Trademark, together with the goodwill of the business symbolized by the Trademark, and all claims arising out of or relating to the use or ownership of the Trademark.

Cidara Therapeutics, Inc.

Signature: 
14719ADD2FF34A0...

Name: Shane Ward
[printed or typed]

Title: Chief operating officer

Date: 12/13/2022